scientific peer-review process and are overseen by the ORP. An NCCN study funded through the grant mechanism is highlighted below. A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor–Naïve Advanced EGFR -Mutant Lung
Search Results
Oncology Research Program
Highlights of the NCCN Oncology Research Program
Harbor a Sensitizing EGFR Mutation or Have Never Smoked Principal Investigator: Joseph Treat, MD Condition: Stage IV nonsquamous non–small cell lung cancer Institution: Fox Chase Cancer Center Patients with non–small cell lung cancer (NSCLC
Highlights of the NCCN Oncology Research Program
Sensitizing EGFR Mutation or Have Never Smoked Principal Investigator: Joseph Treat, MD Condition: Stage IV nonsquamous non–small cell lung cancer Institution: Fox Chase Cancer Center Patients with non–small cell lung cancer (NSCLC) who harbor an EGFR
BPI22-022: Real World Adherence to Biomarker Testing Guidelines That Inform First-Line Treatment Decisions for Patients Newly Diagnosed With Metastatic Non-Small Cell Lung Cancer in the Community Setting
Amy M. Pasmann, William E. Nibley, Scott D. Goldfarb, Veena Shetty, Jon M. Apple, and Anne Shah
Abstracted from charts and an electronic database. The primary objective was to measure the “effective” biomarker testing rate of five major guideline-recommended biomarkers (EGFR, ALK, ROS1, BRAF, and PD-L1), defined as results available to treating
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica Bauman, Lucian R. Chirieac, Thomas A. D'Amico, Malcolm M. DeCamp, Thomas J. Dilling, Michael Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
[eg, echinoderm microtubule-associated protein-like 4]), ROS1 gene rearrangements, and sensitizing EGFR mutations (see “Principles of Pathologic Review” in the complete version of these guidelines, available at NCCN.org [NSCL-A]). Emerging biomarkers
BRAF Mutations in Colorectal Cancer: Clinical Relevance and Role in Targeted Therapy
Rona Yaeger and Leonard Saltz
primary resistance to anti–epidermal growth factor receptor (EGFR) agents by leading to EGFR-independent activation of mitogen-activated protein kinase (MAPK) signaling. BRAF is a signal transduction protein that is downstream of KRAS in the MAPK pathway
Why a One Size Fits All Approach to RAS Might Not Fit Colorectal Cancer
Jonathan M. Loree and Scott Kopetz
Since the discovery that KRAS exon 2 mutations predict a lack of benefit from anti–epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer, our understanding of RAS mutations has expanded considerably. Guidelines now
CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series
Mark Joshua Chang, Wolfram Samlowski, Douglas Fife, Mac Machan, and Raul Meoz
tolerated. Most laCSCC tumors express high levels of epidermal growth factor receptors (EGFR). Cetuximab has shown activity in other EGFR expressing cancers and enhances the effectiveness of radiotherapy. Methods: We performed a retrospective review of
Oncology Research Program
Patients With Resected Stage I–III Non–Small Cell Lung Cancer With EGFR Mutation Principal Investigator: Lecia Sequist, MD, MPH Condition: Non–small cell lung cancer Institution: Massachusetts General Hospital Cancer Center This is a randomized
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr., Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Jose M. Pacheco, Sandip P. Patel, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina Gregory, and Miranda Hughes
factor receptor ( EGFR ) mutations, including EGFR S768I, L861Q , and G719× , based on data showing the efficacy of certain EGFR tyrosine kinase inhibitors (TKIs) for patients with these mutations. All the systemic therapy regimens have been
